Industry

Pharma Q3 preview: Core business, India growth to offset Revlimid pain

January 15, 2026

News Pharma Q3 preview: Core business, India growth to offset Revlimid pain Jessica Jani 3 min read 15 Jan 2026, 05:15 pm IST Indian drugmakers, such as Dr Reddy’s, Cipla, Zydus Lifesciences, and Sun Pharma, inked settlements with Revlimid’s innovator, Mylan, to sell the drug in limited quantities from 2022 until its patent expiry in January 2026. Summary Apart from the Revlimid loss, generic price competition in the US, and the addition of new medical representatives in the India business are likely to impact margins this quarter. Gift this article This is a Mint Premium article gifted to you.

Credit: Livemint

Key Highlights

Subscribe to enjoy similar stories.
Subscribe now As India’s pharmaceutical sector kicks off its earnings season for the quarter ended December on Friday, analysts expect muted margins.
A key reason for this is the loss of patent exclusivity for the blood cancer drug Revlimid in the US.
While the Revlimid loss is expected to hit overall US sales, steady domestic growth and momentum in the base business may soften the impact.
Several Indian drugmakers, such as Dr Reddy’s, Cipla, Zydus Lifesciences, and Sun Pharma, inked settlements with Revlimid’s innovator, Mylan, to sell the drug in limited quantities from 2022 until its patent expiry in January 2026.

Sources

Pharma Q3 preview: Core business, India growth to offset Revlimid pain

This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.